Mesa Reports Q3 Revenue of $65.126M, Beating Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 03 2026
0mins
Reports Q3 revenue $65.126M, consensus $63.23M. "Steady execution and relatively stable markets across Europe and North America helped deliver 3.6% organic revenues growth in 3Q26 versus the prior year, or 5.7% when excluding CG China revenues. Total company growth was 7.2% sequentially, well within our expected growth range. Strong growth in BPD, continued growth in CG excluding China, and a recovery towards normal SDC deliveries overcame strong but expected headwinds in CG China. For the first nine months of FY26, we delivered 3.7% organic revenues growth, but 6.6% when excluding CG China revenues. With continued strong execution across the business and less impactful CG China compares moving forward, we expect our positive momentum to continue in 4Q26" said Gary Owens, Chief Executive Officer of Mesa.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MLAB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MLAB
Wall Street analysts forecast MLAB stock price to fall
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 103.100
Low
83.00
Averages
99.00
High
115.00
Current: 103.100
Low
83.00
Averages
99.00
High
115.00
About MLAB
Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. The Company's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Mesa Laboratories Shares Plunge 19.5% Following Q4 Earnings Report
- Earnings Report Disappointment: Mesa Laboratories reported a Q4 fiscal 2026 adjusted operating income of $3.30 per share, exceeding Wall Street's expectations by $1.76, yet its sales of $63.72 million fell short, leading to a significant stock price drop.
- Sales Miss: The company's revenue was approximately $1.48 million below the average analyst target, indicating weak market demand that could negatively impact future revenue growth and investor confidence.
- Stock Price Volatility: As of 3:30 p.m. ET, Mesa's stock plummeted 19.5% to $86.46, reflecting strong investor reaction to the earnings report and heightened concerns about the company's future performance.
- Uncertain Future Outlook: CEO Siddhartha Kadia is conducting an internal review and expects to provide full-year guidance with the Q2 report, although management noted some easing of export controls for peptide systems, leaving future growth prospects uncertain.
See More
Mesa Laboratories Reports Reduced Q4 Loss
- Loss Improvement: Mesa Laboratories reported a fourth-quarter loss of $4.14 million, or $0.75 per share, which is an improvement from last year's loss of $7.11 million and $1.31 per share, indicating a positive trend in financial performance.
- Revenue Growth: The company's revenue for the quarter reached $63.72 million, up 2.6% from $62.13 million last year, suggesting enhanced sales capabilities in the market despite the ongoing losses.
- Year-over-Year Comparison: The reduction in losses by 39.5% compared to last year may reflect the company's proactive efforts in cost control and operational efficiency, although further improvements are necessary to achieve profitability.
- Future Outlook: While still facing losses, the revenue growth and reduction in losses lay a foundation for potential recovery and profitability, which may attract investor interest in the company's rebound opportunities.
See More
Mesa Laboratories Q4 Earnings Report Analysis
- Disappointing Earnings: Mesa Laboratories reported a Q4 GAAP EPS of -$0.75, falling short of market expectations, indicating challenges in profitability that could undermine investor confidence.
- Lackluster Revenue Growth: The company posted revenue of $63.72 million, a 2.5% year-over-year increase, yet it missed expectations by $1.48 million, reflecting weak market demand and intensified competitive pressures.
- New CEO Appointment: Mesa Laboratories has appointed a new CEO, aiming to drive strategic transformation through leadership change, with hopes of improving company performance and market standing.
- Analyst Rating Concerns: Seeking Alpha's Quant Rating on Mesa Laboratories indicates a cautious market outlook on the company's future performance, which may influence investor decisions and stock price volatility.
See More
Mesa Laboratories to Release Q4 and FY 2026 Financial Results
- Earnings Release Schedule: Mesa Laboratories plans to issue its financial results for the fourth quarter and fiscal year ending March 31, 2026, at approximately 6:00 A.M. Eastern Time on May 27, 2026, which is expected to provide investors with critical performance data and future outlook.
- Company Background: Mesa Laboratories is a global leader in the design and manufacture of life science tools and critical quality control solutions, focusing on regulated applications in the pharmaceutical, healthcare, and medical device industries, dedicated to enhancing product integrity and safety.
- Market Positioning: The products and services offered by Mesa Laboratories aim to help customers ensure product quality, increase patient and worker safety, and improve quality of life globally, highlighting its significant role in the industry.
- Management Contact Information: Mesa Laboratories' President and CEO Siddhartha Kadia and Vice President and CFO John Sakys can be reached at 1-303-987-8000 for further company information and insights into financial data.
See More
Citigroup, Maximus, Lindsay Declare Quarterly Dividends
- Citigroup Dividend: Citigroup's Board of Directors declared a quarterly cash dividend of $0.60 per share, payable on May 22, 2026, to shareholders of record as of May 4, 2026, demonstrating the company's ongoing commitment to shareholder returns.
- Maximus Dividend Approval: Maximus announced a quarterly cash dividend of $0.33 per share, set to be paid on June 1, 2026, with a record date of May 15, 2026, reflecting the company's stable profitability in the government services sector.
- Lindsay Dividend Declaration: Lindsay declared a quarterly cash dividend of $0.37 per share, payable on May 29, 2026, to shareholders of record as of May 15, 2026, indicating continued growth in the irrigation and infrastructure equipment market.
- MV Oil Trust Distribution: MV Oil Trust announced a distribution of net profits for the quarter ending March 31, 2026, with unitholders receiving $0.170 per unit, totaling $1,955,000, showcasing the trust's profitability and stable cash flow.
See More
Mesa Laboratories Declares Quarterly Dividend of $0.16
- Quarterly Dividend Announcement: Mesa Laboratories declares a quarterly dividend of $0.16 per share, consistent with previous distributions, indicating the company's stable cash flow and shareholder return strategy, which is expected to bolster investor confidence.
- Dividend Yield: The forward yield of 0.7% reflects the company's robust performance in the current market environment, potentially attracting income-seeking investors looking for reliable returns.
- Financial Performance Beats Expectations: Mesa Laboratories reports a GAAP EPS of $0.65, exceeding expectations by $0.37, with revenue of $65.13 million surpassing estimates by $1.9 million, showcasing the company's strong growth potential in the medical device sector.
- Management Change: The appointment of a new CEO may bring a fresh strategic direction and management style, further enhancing the company's innovation and competitive edge in the healthcare industry.
See More
Mesa Laboratories Shares Plunge 19.5% Following Q4 Earnings Report
- Earnings Report Disappointment: Mesa Laboratories reported a Q4 fiscal 2026 adjusted operating income of $3.30 per share, exceeding Wall Street's expectations by $1.76, yet its sales of $63.72 million fell short, leading to a significant stock price drop.
- Sales Miss: The company's revenue was approximately $1.48 million below the average analyst target, indicating weak market demand that could negatively impact future revenue growth and investor confidence.
- Stock Price Volatility: As of 3:30 p.m. ET, Mesa's stock plummeted 19.5% to $86.46, reflecting strong investor reaction to the earnings report and heightened concerns about the company's future performance.
- Uncertain Future Outlook: CEO Siddhartha Kadia is conducting an internal review and expects to provide full-year guidance with the Q2 report, although management noted some easing of export controls for peptide systems, leaving future growth prospects uncertain.
See More
Mesa Laboratories Reports Reduced Q4 Loss
- Loss Improvement: Mesa Laboratories reported a fourth-quarter loss of $4.14 million, or $0.75 per share, which is an improvement from last year's loss of $7.11 million and $1.31 per share, indicating a positive trend in financial performance.
- Revenue Growth: The company's revenue for the quarter reached $63.72 million, up 2.6% from $62.13 million last year, suggesting enhanced sales capabilities in the market despite the ongoing losses.
- Year-over-Year Comparison: The reduction in losses by 39.5% compared to last year may reflect the company's proactive efforts in cost control and operational efficiency, although further improvements are necessary to achieve profitability.
- Future Outlook: While still facing losses, the revenue growth and reduction in losses lay a foundation for potential recovery and profitability, which may attract investor interest in the company's rebound opportunities.
See More
Mesa Laboratories Q4 Earnings Report Analysis
- Disappointing Earnings: Mesa Laboratories reported a Q4 GAAP EPS of -$0.75, falling short of market expectations, indicating challenges in profitability that could undermine investor confidence.
- Lackluster Revenue Growth: The company posted revenue of $63.72 million, a 2.5% year-over-year increase, yet it missed expectations by $1.48 million, reflecting weak market demand and intensified competitive pressures.
- New CEO Appointment: Mesa Laboratories has appointed a new CEO, aiming to drive strategic transformation through leadership change, with hopes of improving company performance and market standing.
- Analyst Rating Concerns: Seeking Alpha's Quant Rating on Mesa Laboratories indicates a cautious market outlook on the company's future performance, which may influence investor decisions and stock price volatility.
See More
Mesa Laboratories to Release Q4 and FY 2026 Financial Results
- Earnings Release Schedule: Mesa Laboratories plans to issue its financial results for the fourth quarter and fiscal year ending March 31, 2026, at approximately 6:00 A.M. Eastern Time on May 27, 2026, which is expected to provide investors with critical performance data and future outlook.
- Company Background: Mesa Laboratories is a global leader in the design and manufacture of life science tools and critical quality control solutions, focusing on regulated applications in the pharmaceutical, healthcare, and medical device industries, dedicated to enhancing product integrity and safety.
- Market Positioning: The products and services offered by Mesa Laboratories aim to help customers ensure product quality, increase patient and worker safety, and improve quality of life globally, highlighting its significant role in the industry.
- Management Contact Information: Mesa Laboratories' President and CEO Siddhartha Kadia and Vice President and CFO John Sakys can be reached at 1-303-987-8000 for further company information and insights into financial data.
See More
Citigroup, Maximus, Lindsay Declare Quarterly Dividends
- Citigroup Dividend: Citigroup's Board of Directors declared a quarterly cash dividend of $0.60 per share, payable on May 22, 2026, to shareholders of record as of May 4, 2026, demonstrating the company's ongoing commitment to shareholder returns.
- Maximus Dividend Approval: Maximus announced a quarterly cash dividend of $0.33 per share, set to be paid on June 1, 2026, with a record date of May 15, 2026, reflecting the company's stable profitability in the government services sector.
- Lindsay Dividend Declaration: Lindsay declared a quarterly cash dividend of $0.37 per share, payable on May 29, 2026, to shareholders of record as of May 15, 2026, indicating continued growth in the irrigation and infrastructure equipment market.
- MV Oil Trust Distribution: MV Oil Trust announced a distribution of net profits for the quarter ending March 31, 2026, with unitholders receiving $0.170 per unit, totaling $1,955,000, showcasing the trust's profitability and stable cash flow.
See More
Mesa Laboratories Declares Quarterly Dividend of $0.16
- Quarterly Dividend Announcement: Mesa Laboratories declares a quarterly dividend of $0.16 per share, consistent with previous distributions, indicating the company's stable cash flow and shareholder return strategy, which is expected to bolster investor confidence.
- Dividend Yield: The forward yield of 0.7% reflects the company's robust performance in the current market environment, potentially attracting income-seeking investors looking for reliable returns.
- Financial Performance Beats Expectations: Mesa Laboratories reports a GAAP EPS of $0.65, exceeding expectations by $0.37, with revenue of $65.13 million surpassing estimates by $1.9 million, showcasing the company's strong growth potential in the medical device sector.
- Management Change: The appointment of a new CEO may bring a fresh strategic direction and management style, further enhancing the company's innovation and competitive edge in the healthcare industry.
See More
